FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Hyperion Trading Segregated Portfolio 2. Date of Event Requiring Statement (Month/Day/Year) 11/20/2012 3. Issuer Name and Ticker or Trading Symbol Raptor Pharmaceutical Corp [RPTP] (Last) (First) (Middle) C/O TMF LTD. GRAND PAVILLION COMM. CTR, 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) GRAND CAYMAN, E9 KY1-1003 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock, par value $0.001 per share (1) 5,176,500 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Contracts for Difference (2)	  (2)	  (2)	Common Stock	10,000	$ 5.2 (2)	D	Â
Contracts for Difference (2)	  (2)	  (2)	Common Stock	10,000	$ 5.18 (2)	D	Â
Contracts for Difference (2)	  (2)	  (2)	Common Stock	10,000	$ 5.16 (2)	D	Â
Contracts for Difference (2)	  (2)	  (2)	Common Stock	10,000	$ 5.16 (2)	D	Â
Contracts for Difference (2)	  (2)	  (2)	Common Stock	10,000	$ 5.16 (2)	D	Â
Contracts for Difference (2)	  (2)	  (2)	Common Stock	2,450	$ 5.16 (2)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Hyperion Trading Segregated Portfolio C/O TMF LTD. GRAND PAVILLION COMM. CTR 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 GRAND CAYMAN, E9 KY1-1003	Â	  X	Â	Â

Signatures

/s/ David P.M. Blair and Richard A. Reinert		08/19/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The shares of common stock, $0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Star Arrow Funds Expertise Ltd, a company organized under the laws of Anguilla ("Star").
(2)	On November 20, 2012, the Reporting Person held Contracts for Difference of the Common Shares (the "CFDs") reported herein with a securities broker (the "Issuer of the CFDs"), upon which, pursuant to an agreement between the Reporting Person and the Issuer of the CFDs, upon conversion of the CFDs (i) the Issuer of the CFDs would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion or, (ii) in the case that the purchase price of the CFDs (represented in column 4 of Table II) is less than the market price of the Common Shares at the time of conversion, the Reporting Person would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion. As of November 20, 2012, the Reporting Person and the Issuer of the CFDs had not converted any of the CFDs.
  Remarks: 1.  The Common Shares and CFDs reported herein represent securities (the "Securities") held by the Reporting Person. Pursuant to Reg. Section 240.16a-1(a)(1), Star, as the investment manager of the Reporting Person, is not deemed a beneficial owner of the Securities held by the Reporting Person or any other account managed by Star. In the event that Star is deemed a beneficial owner of the Securities held by the Reporting Person or any other account managed by Star, pursuant to Reg. Section 240.16a-1(a)(2), its beneficial ownership is limited to its pecuniary interest, if any, in such Securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.